Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Given Consensus Rating of “Hold” by Brokerages

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) has been assigned an average recommendation of “Hold” from the five research firms that are covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and three have issued a buy recommendation on the company. The average 1 year price objective among brokerages that have covered the stock in the last year is $31.00.

A number of research firms recently commented on ETON. Craig Hallum boosted their price objective on shares of Eton Pharmaceuticals from $29.00 to $30.00 and gave the stock a “buy” rating in a report on Tuesday, March 3rd. Weiss Ratings reissued a “sell (d-)” rating on shares of Eton Pharmaceuticals in a research note on Thursday, January 22nd. Wall Street Zen downgraded shares of Eton Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, December 13th. HC Wainwright lifted their price target on shares of Eton Pharmaceuticals from $35.00 to $37.00 and gave the company a “buy” rating in a research report on Monday, March 2nd. Finally, Zacks Research upgraded shares of Eton Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Thursday, January 1st.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in ETON. Divisadero Street Capital Management LP bought a new position in shares of Eton Pharmaceuticals during the second quarter valued at approximately $7,092,000. Geode Capital Management LLC increased its position in shares of Eton Pharmaceuticals by 98.8% during the 2nd quarter. Geode Capital Management LLC now owns 592,865 shares of the company’s stock valued at $8,450,000 after purchasing an additional 294,617 shares during the period. Soleus Capital Management L.P. acquired a new stake in shares of Eton Pharmaceuticals in the second quarter valued at $4,061,000. Millennium Management LLC lifted its stake in Eton Pharmaceuticals by 156.3% during the first quarter. Millennium Management LLC now owns 355,929 shares of the company’s stock valued at $4,620,000 after purchasing an additional 217,042 shares during the last quarter. Finally, Oberweis Asset Management Inc. purchased a new stake in shares of Eton Pharmaceuticals during the third quarter valued at $4,180,000. 27.86% of the stock is owned by institutional investors and hedge funds.

More Eton Pharmaceuticals News

Here are the key news stories impacting Eton Pharmaceuticals this week:

• Positive Sentiment: HC Wainwright raised several near‑ and long‑term EPS forecasts (Q2/Q3/Q4 2026 and FY2026/FY2028/FY2029) and maintains a “Buy” rating with a $37 price target — a signal of improving analyst expectations for ETON’s revenue/profit trajectory. HC Wainwright research note (MarketBeat)
• Positive Sentiment: An independent note raised Eton’s price target to $30, providing another analyst-based floor for upside expectations. Eton Pharmaceuticals (NASDAQ:ETON) Price Target Raised to $30.00
• Neutral Sentiment: Reported “large increase” in short interest is effectively a data anomaly (short interest reported as 0 shares and a 0.0 days ratio), so it should not materially affect positioning unless updated with real figures.
• Negative Sentiment: A separate headline framed an earnings estimate as “pessimistic,” which likely contributed to selling pressure despite the published EPS upgrades — the mixed messaging can prompt profit‑taking or caution among short‑term holders. HC Wainwright Issues Pessimistic Estimate for ETON Earnings

Eton Pharmaceuticals Stock Down 2.6%

Shares of NASDAQ ETON opened at $16.80 on Friday. The business has a 50-day moving average price of $16.23 and a 200 day moving average price of $17.25. The stock has a market cap of $450.58 million, a PE ratio of -67.20 and a beta of 1.19. The company has a quick ratio of 1.25, a current ratio of 1.63 and a debt-to-equity ratio of 1.19. Eton Pharmaceuticals has a 52-week low of $11.09 and a 52-week high of $23.00.

About Eton Pharmaceuticals

Eton Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing, manufacturing and commercializing generic and proprietary pharmaceutical products for patients with rare and underserved diseases. Headquartered in West Palm Beach, Florida, the company leverages its expertise in hormone therapies and complex molecules to address treatment areas where patient need is high and competition is limited. Since its founding in 2016, Eton has sought to build a diversified portfolio that combines established generic medicines with targeted branded offerings.

The company’s product lineup includes thyroid hormone replacements such as desiccated thyroid and liothyronine, as well as pyrimethamine tablets indicated for toxoplasmosis.